Gomez-Navarro J - Search Results

1

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Ribas A, et al. J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7. J Clin Oncol. 2013. PMID: 23295794 Free PMC article. Clinical Trial.

2

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. Ribas A, et al. J Clin Oncol. 2005 Dec 10;23(35):8968-77. doi: 10.1200/JCO.2005.01.109. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204013 Clinical Trial.

3

Phase I/II trial of tremelimumab in patients with metastatic melanoma.

Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. Camacho LH, et al. J Clin Oncol. 2009 Mar 1;27(7):1075-81. doi: 10.1200/JCO.2008.19.2435. Epub 2009 Jan 12. J Clin Oncol. 2009. PMID: 19139427 Clinical Trial.

4

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.

Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA. Kirkwood JM, et al. Clin Cancer Res. 2010 Feb 1;16(3):1042-8. doi: 10.1158/1078-0432.CCR-09-2033. Epub 2010 Jan 19. Clin Cancer Res. 2010. PMID: 20086001 Clinical Trial.

5

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.

Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. Ribas A, et al. Clin Cancer Res. 2009 Oct 1;15(19):6267-76. doi: 10.1158/1078-0432.CCR-09-1254. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789309 Free PMC article. Clinical Trial.

6

Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.

Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. Ribas A, et al. J Nucl Med. 2010 Mar;51(3):340-6. doi: 10.2967/jnumed.109.070946. Epub 2010 Feb 11. J Nucl Med. 2010. PMID: 20150263 Free article. Clinical Trial.

7

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.

Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. Ribas A, et al. J Transl Med. 2012 Nov 21;10:236. doi: 10.1186/1479-5876-10-236. J Transl Med. 2012. PMID: 23171508 Free PMC article. Clinical Trial.

8

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.

Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB. Millward M, et al. Br J Cancer. 2013 May 28;108(10):1998-2004. doi: 10.1038/bjc.2013.227. Epub 2013 May 7. Br J Cancer. 2013. PMID: 23652314 Free PMC article. Clinical Trial.

9

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.

Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, Canniff PC, Sharma A, Gomez-Navarro J. Ribas A, et al. Oncologist. 2007 Jul;12(7):873-83. doi: 10.1634/theoncologist.12-7-873. Oncologist. 2007. PMID: 17673618 Free article. Review.

10

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.

Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. Ribas A, et al. Clin Cancer Res. 2009 Jan 1;15(1):390-9. doi: 10.1158/1078-0432.CCR-08-0783. Clin Cancer Res. 2009. PMID: 19118070

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page